Dexamethasone-functionalized gels induce osteogenic differentiation of encapsulated hMSCs.

Synthetic hydrogels represent highly controlled environments for three-dimensional culture of human mesenchymal stem cells (hMSCs). Encapsulated hMSCs are presented with a "blank" environment, and this environment can be closely controlled in order to elicit an osteogenic response. In vitro, dexamethasone is an efficient and reliable factor that leads to the osteogenic differentiation of human mesenchymal stem cells (hMSCs). The aim of this work was to develop a dexamethasone-releasing poly(ethylene glycol) (PEG)-based hydrogel scaffold to deliver dexamethasone to encapsulated cells in a sustained manner. To accomplish this goal, dexamethasone was covalently linked to a photoreactive mono-acrylated PEG molecule through a degradable lactide bond, and this molecule was covalently incorporated into the PEG hydrogel during photopolymerization. Over time, hydrolysis of the ester bonds resulted in dexamethasone release from the gel. The biological activity of the released dexamethasone was verified in monolayer cell culture and in three-dimensional culture (i.e., in the gel) by the ability of hMSCs to express osteogenic genes, including alkaline phosphatase, osteopontin, and core binding factor alpha 1, as measured using real-time reverse transcription polymerase chain reaction (RT-PCR). These studies indicate that encapsulated hMSCs are capable of osteogenic differentiation in response to released dexamethasone.

[1]  K. Anseth,et al.  Synthetic hydrogel niches that promote hMSC viability. , 2005, Matrix biology : journal of the International Society for Matrix Biology.

[2]  Kristi S Anseth,et al.  In vitro osteogenic differentiation of human mesenchymal stem cells photoencapsulated in PEG hydrogels. , 2004, Journal of biomedical materials research. Part A.

[3]  J. Hubbell,et al.  The effect of the linker on the hydrolysis rate of drug-linked ester bonds. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[4]  A. Osyczka,et al.  Different Effects of BMP-2 on Marrow Stromal Cells from Human and Rat Bone , 2004, Cells Tissues Organs.

[5]  C. Maniatopoulos,et al.  Bone formation in vitro by stromal cells obtained from bone marrow of young adult rats , 1988, Cell and Tissue Research.

[6]  Hwal Suh,et al.  Sustained release of ascorbate-2-phosphate and dexamethasone from porous PLGA scaffolds for bone tissue engineering using mesenchymal stem cells. , 2003, Biomaterials.

[7]  A. Goldstein,et al.  Effect of dexamethasone withdrawal on osteoblastic differentiation of bone marrow stromal cells , 2003, Journal of cellular biochemistry.

[8]  W. Saltzman,et al.  Organosilicate-polymer drug delivery systems: controlled release and enhanced mechanical properties. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[9]  G. Reilly,et al.  BMP Responsiveness in Human Mesenchymal Stem Cells , 2003, Connective tissue research.

[10]  S. Santavirta,et al.  Recombinant Human Bone Morphogenetic Protein-2 for Treatment of Open Tibial Fractures: A Prospective, Controlled, Randomized Study of Four Hundred and Fifty Patients , 2002, The Journal of bone and joint surgery. American volume.

[11]  Yan Zhang,et al.  Synthesis of an enzyme-dependent prodrug and evaluation of its potential for colon targeting. , 2002, World journal of gastroenterology.

[12]  J. Aubin,et al.  Expression of leukemia inhibitory factor (LIF)/interleukin-6 family cytokines and receptors during in vitro osteogenesis: differential regulation by dexamethasone and LIF. , 2002, Bone.

[13]  Stephanie J Bryant,et al.  In situ forming degradable networks and their application in tissue engineering and drug delivery. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[14]  Daniel Chappard,et al.  Phenotypic effects of continuous or discontinuous treatment with dexamethasone and/or calcitriol on osteoblasts differentiated from rat bone marrow stromal cells , 2002, Journal of cellular biochemistry.

[15]  D. Mooney,et al.  Hydrogels for combination delivery of antineoplastic agents. , 2001, Biomaterials.

[16]  J. Lane BMPs: why are they not in everyday use? , 2001, The Journal of bone and joint surgery. American volume.

[17]  D J Mooney,et al.  Sustained and controlled release of daunomycin from cross-linked poly(aldehyde guluronate) hydrogels. , 2000, Journal of pharmaceutical sciences.

[18]  E. Burger,et al.  Bone morphogenetic proteins in human bone regeneration. , 2000, European journal of endocrinology.

[19]  M. Pittenger,et al.  Multilineage potential of adult human mesenchymal stem cells. , 1999, Science.

[20]  A. Metters,et al.  Fundamental studies of biodegradable hydrogels as cartilage replacement materials. , 1999, Biomedical sciences instrumentation.

[21]  A. Mikos,et al.  Osteoblastic phenotype of rat marrow stromal cells cultured in the presence of dexamethasone, β‐glycerolphosphate, and L‐ascorbic acid , 1998, Journal of cellular biochemistry.

[22]  Kent J. Voorhees,et al.  Hydrolysis of Polylactic Acid (PLA) and Polycaprolactone (PCL) in Aqueous Acetonitrile Solutions: Autocatalysis , 1998 .

[23]  S. Bruder,et al.  Osteogenic differentiation of purified, culture‐expanded human mesenchymal stem cells in vitro , 1997, Journal of cellular biochemistry.

[24]  Su‐Li Cheng,et al.  Differentiation of human bone marrow osteogenic stromal cells in vitro: induction of the osteoblast phenotype by dexamethasone. , 1994, Endocrinology.

[25]  B. Borremans,et al.  Characterization of a 5-fluorouracil-enriched osteoprogenitor population of the murine bone marrow. , 1993, Blood.

[26]  C. McCulloch,et al.  Dexamethasone recruitment of self-renewing osteoprogenitor cells in chick bone marrow stromal cell cultures. , 1992, Blood.

[27]  J. Aubin,et al.  Determination of the capacity for proliferation and differentiation of osteoprogenitor cells in the presence and absence of dexamethasone. , 1990, Developmental biology.

[28]  S. Wientroub,et al.  Bone marrow‐derived stromal cell line expressing osteoblastic phenotype in vitro and osteogenic capacity in vivo , 1989, Journal of cellular physiology.